{"nctId":"NCT01146951","briefTitle":"A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients (Study E2080-J081-304)","startDateStruct":{"date":"2010-06"},"conditions":["Lennox-Gastaut Syndrome"],"count":66,"armGroups":[{"label":"Rufinamide (E2080)","type":"EXPERIMENTAL","interventionNames":["Drug: Rufinamide (E2080)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Rufinamide (E2080)","otherNames":["E2080"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria\n\n1. Participants who are diagnosed as Lennox-Gastaut syndrome with tonic/atonic seizures and atypical absence seizures (A history of atypical absence seizures will also be incorporated).\n2. Participants who had a slow spike-and-wave pattern in an electroencephalogram within 6 months prior to the enrollment for the Observation Period.\n3. Participants who had at least a total of 90 seizures in the 28 days prior to the enrollment for the Observation Period.\n4. Participants who have been on 1 - 3 anti-epileptic drugs from 28 days prior to the enrollment for the Observation Period and have not changed the type of the anti-epileptic drugs.\n5. Participants who have not changed the type nor the dose or administration of the anti-epileptic drugs they are taking in the Observation Period.\n\nExclusion criteria;\n\n1. Participants who had a history of generalized tonic-clonic status epilepticus within baseline.\n2. Participants who received drug therapy at least 4 times to be rescued from status epilepticus within baseline.\n3. Participants who had a history of hypoxia which needed emergency resuscitation within 12 months prior to the Treatment Period.\n4. Participants who were on a ketogenic diet or have received adrenocorticotropic hormone (ACTH) therapy or Vitamin B6 therapy within 6 months prior to the Treatment Period.\n5. Participants who had a history of suicide attempt within the 1 year prior to the Treatment Period.\n6. Participants who had a history of or has an allergy to triazole compound.\n7. Participants who have clinically significant electrocardiogram abnormalities at baseline.\n8. Participants who are pregnant, who may be pregnant, who are lactating or who wish to be pregnant.","healthyVolunteers":false,"sex":"ALL","minimumAge":"4 Years","maximumAge":"30 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change in Tonic-Atonic Seizure Frequency From Baseline (Per 28 Days)","description":"The sum of the frequencies of tonic seizures and atonic seizures was defined as the \"tonic-atonic seizure frequency\" and the percent change in tonic-atonic seizure frequency per 28 days was assessed. The percent change in tonic-atonic seizure frequency was calculated using the tonic-atonic seizure frequency per 28 days of the Observation Period as the baseline and the tonic-atonic seizure frequency per 28 days of the Treatment Period as the post-treatment value. Percentage change in tonic - atonic seizure frequency was calculated as follows: \\[100 x (post-treatment value - baseline)/ baseline\\].\n\nThe frequency of epileptic seizures was recorded in the seizure diary by the recorder. Seizure frequency was counted based on the classification established by the International League Against Epilepsy (ILAE). The diary recorder monitored the participant and recorded the seizure diary in a consistent manner, and continued these practices throughout the study period.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.20","spread":null},{"groupId":"OG001","value":"-3.25","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Achieving a 50% Reduction in Tonic-atonic Seizure Frequency","description":"50% Responder Rate in Tonic-Atonic Seizure Frequency was presented as the number of participants who achieved a 50% reduction in tonic-atonic seizure frequency.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change in Total Seizure Frequency (Per 28 Days)","description":"Percent change in the total seizure frequency (per 28 days) was calculated using the total seizure frequency per 28 days of the Observation Period as the baseline and the total seizure frequency per 28 days of the Treatment Period as the post-treatment value. Percentage change in total seizure frequency was calculated as follows: \\[100 x (post-treatment value - baseline)/ baseline\\].","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-32.90","spread":null},{"groupId":"OG001","value":"-3.05","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage Change in the Frequency of Seizures Other Than Tonic-atonic Seizures (Per 28 Days)","description":"Percent change in the frequency of seizures other than tonic-atonic seizures (per 28 days) was calculated using the total seizure frequency per 28 days of the Observation Period as the baseline and the total seizure frequency per 28 days of the Treatment Period as the post-treatment value. Percentage change in total seizure frequency was calculated as follows: \\[100 x (post-treatment value - baseline)/ baseline\\].\n\nSeizures analyzed other than tonic-atonic seizures included:\n\nPartial seizure freq. (frequency), Absence seizure, Atyp. (atypical) absence seizure, Myoclonic seizure, Clonic seizure, Tonic seizure, Tonic-clonic seizure, Atonic seizure, \\& Uncla. (unclassified) epileptic seizure.\n\nThe frequency of epileptic seizures was recorded in the diary by the recorder. Seizure frequency was counted based on the classification established by the International League Against Epilepsy (ILAE). The diary recorder monitored the participant and recorded the seizure diary in a consistent manner.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-52.20","spread":null},{"groupId":"OG001","value":"4.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.40","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-59.00","spread":null},{"groupId":"OG001","value":"-21.10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-52.35","spread":null},{"groupId":"OG001","value":"6.60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-81.20","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.20","spread":null},{"groupId":"OG001","value":"-3.60","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-57.35","spread":null},{"groupId":"OG001","value":"2.35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-63.10","spread":null},{"groupId":"OG001","value":"-6.10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-88.70","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Global Impression of Change (CGIC)","description":"CGIC in participants with Lennox-Gastaut Syndrome (LGS) relative to placebo was presented as number of participants in each category at the final assessment (last observation carried forward \\[LOCF\\]) \\& at Week 12 of the Treatment Period. The investigator assessed the CGIC by comparing the participants' condition during the 4 weeks immediately before the completion (or discontinuation \\[d/c\\]) of the Treatment Period to his/her condition during the 4-week Observation Period (for participants who d/c'd the study during the Treatment Period, the CGIC was assessed by comparing the participant's condition from the start to discontinuation of the study treatment to his/her condition during the 4-week Observation Period).\n\nThe CGIC was assessed according to the following 7-grade scale based on the frequency \\& severity of seizures, AEs, and overall conditions of daily life.\n\nMarkedly improved, Improved, Slightly improved, Unchanged, Slightly worsened, Worsened, Markedly worsened.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":29},"commonTop":["Nasopharyngitis","Status Epilepticus","Decreased Appetite","Somnolence","Vomiting"]}}}